Abstract Number: 2385 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Chinese Herbal Medicine Biqi Capsule Combined with Methotrexate in Patients with Rheumatoid Arthritis: A Pilot Study
Background/Purpose: In recent years, the combination therapies of conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) with Chinses medicine has prevailed for the treatment of rheumatoid arthritis…Abstract Number: 1502 • 2018 ACR/ARHP Annual Meeting
Predicting Response to Methotrexate Therapy in New-Onset RA: No Value of Adding Protein Biomarkers to Clinical Predictors
Background/Purpose: We previously identified higher disease activity score assessing 28 joints (DAS28) at baseline, current smoking and no alcohol consumption as clinical predictors for inadequate…Abstract Number: 2985 • 2018 ACR/ARHP Annual Meeting
Achievement of Remission in Two Early Rheumatoid Arthritis Inception Cohorts Implementing Different Treat-to-Target Strategies
Background/Purpose: Treat-to-target (T2T) has become a key element in the management of rheumatoid arthritis (RA). Several different measures exist to define the preferred treatment target…Abstract Number: 1889 • 2018 ACR/ARHP Annual Meeting
Patterns of Glucocorticoid Use and Provider-Level Variation in a Commercially Insured Incident Rheumatoid Arthritis Population
Background/Purpose: Glucocorticoids (GC) reduce RA-related disability and joint damage; RA guidelines endorse short term use during DMARD initiation and flares. Long-term high-dose GC exposure (>3…Abstract Number: 1923 • 2018 ACR/ARHP Annual Meeting
Treating Rheumatoid Arthritis to Target: Is Low Disease Activity Good Enough?
Treating Rheumatoid Arthritis To Target: Is Low Disease Activity Good Enough? Background/Purpose: It is now widely recognised that treat-to-target (T2T) principles in rheumatoid arthritis (RA)…Abstract Number: 1937 • 2018 ACR/ARHP Annual Meeting
Low-Dose IL-2 Restored Reduced Regulatory T Cells in Patients with Rheumatoid Arthritis
Background/Purpose: Patients with rheumatoid arthritis (RA) have lymphocyte dysfunction characterized by deficiency or dysfunction of regulatory T cells (Tregs), which plays crucial roles in immune tolerance. Low dose IL-2…Abstract Number: 1938 • 2018 ACR/ARHP Annual Meeting
A Phase IIb Dose-Ranging Study of Anti-GM-CSF with Methotrexate Treatment in Patients with Rheumatoid Arthritis (RA) and an Inadequate Response to Methotrexate
Background/Purpose: GSK3196165 is a high-affinity anti-GM-CSF cytokine IgG mAb currently in development for RA, with reported efficacy using IV dosing. This study evaluated the efficacy…Abstract Number: 1939 • 2018 ACR/ARHP Annual Meeting
Sirolimus Treatment in Patients with Refractory Rheumatoid Arthritis: A Double-Arm, Open-Label, phase1/2 Trail
Background/Purpose: Patients with refractory rheumatoid arthritis (RA) have T-cell dysfunction that associates the activation of mTOR that is inhibited by rapamycin, which has been developed…Abstract Number: 2054 • 2018 ACR/ARHP Annual Meeting
In Rheumatoid Arthritis, Changes in Autoantibody Levels Do Not Associate with Treatment Response, but Are a Reflection of Treatment Intensity
Background/Purpose: Rheumatoid arthritis (RA) is characterized by the presence of autoantibodies like rheumatoid factor (RF), anti-cyclic citrullinated peptide-2 (anti-CCP2), & anti-carbamylated protein (anti-CarP) antibodies. It…Abstract Number: 2344 • 2018 ACR/ARHP Annual Meeting
Treatment Modes in Rheumatoid Arthritis: Moving Toward Shared Decision-Making
Background/Purpose: Treatment recommendations in RA emphasize shared decision-making,1 but little is known about patient (pt) perspectives. Through qualitative research, we aim to understand pt preferences…Abstract Number: 134 • 2018 ACR/ARHP Annual Meeting
Exploration of T-Cell Signatures Following TCR Stimulation Using Single Cell RNA-Seq to Inform Treatment Response Studies in Rheumatoid Arthritis
Background/Purpose: For rheumatoid arthritis (RA), as with many other rheumatic diseases, the importance of determining which therapy will work best, early in disease, to prevent…Abstract Number: 2510 • 2018 ACR/ARHP Annual Meeting
A Phase IIa Mechanistic Study of Anti-GM-CSF (GSK3196165) with Methotrexate Treatment in Patients with Rheumatoid Arthritis (RA) and an Inadequate Response to Methotrexate
Background/Purpose: GSK3196165 is a high-affinity anti-GM-CSF cytokine IgG mAb currently in development for RA, with reported efficacy using IV dosing. This study evaluated the effects…Abstract Number: 555 • 2018 ACR/ARHP Annual Meeting
Three Year Outcomes of Patients with Elderly-Onset Rheumatoid Arthritis Treated with a Therapeutic Strategy Targeting Low Disease Activity, and Impact of Adverse Events on Physical Function
Background/Purpose: The aim of this study was to evaluate three year outcomes of patients with elderly-onset RA (EORA) who were treated with a therapeutic strategy…Abstract Number: 2538 • 2018 ACR/ARHP Annual Meeting
Rapamycin Induces Remission in Patients with Newly Diagnosed Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation of the joints.We found that there was an imbalance between Th17 and Treg…Abstract Number: 561 • 2018 ACR/ARHP Annual Meeting
U-Act-Early Trial 3 Years Follow-up: Radiographic Joint Damage and Use of Bdmards over 5 Years in Early RA Patients Treated-to-Target with Strategies Initiating Tocilizumab, Methotrexate or Their Combination
Background/Purpose: The U-Act-Early trial was a 2-year multicentre, double-blind, randomized, placebo-controlled trial in early (DMARD-naïve) RA patients treated to the target of remission, with step-up…
- 1
- 2
- 3
- …
- 10
- Next Page »